Published in J Clin Virol on March 08, 2011
Effects of Physiotherapy in the Treatment of Neurogenic Bladder in Patients Infected With Human T-Lymphotropic Virus 1. Urology (2015) 1.97
HTLV tax: a fascinating multifunctional co-regulator of viral and cellular pathways. Front Microbiol (2012) 1.16
Neurological Manifestations in Human T-Cell Lymphotropic Virus Type 1 (HTLV-1)-Infected Individuals Without HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis: A Longitudinal Cohort Study. Clin Infect Dis (2015) 0.92
HTLV-1 uveitis. Front Microbiol (2012) 0.89
Human T-lymphotropic Virus Type I (HTLV-I) Proviral Load and Clinical Features in Iranian HAM/TSP Patients: Comparison of HTLV-I Proviral Load in HAM/TSP Patients. Iran J Basic Med Sci (2013) 0.85
"HTLV-I Infection" Twenty-Year Research in Neurology Department of Mashhad University of Medical Sciences. Iran J Basic Med Sci (2013) 0.82
Xerostomia due to systemic disease: a review of 20 conditions and mechanisms. Ann Med Health Sci Res (2014) 0.79
Neurological manifestations in individuals with HTLV-1-associated myelopathy/tropical spastic paraparesis in the Amazon. Spinal Cord (2015) 0.78
Dermatological manifestations of individuals infected with human T cell lymphotropic virus type I (HTLV-I). Int J Dermatol (2013) 0.76
Psychiatric Disorders in HTLV-1-Infected Individuals with Bladder Symptoms. PLoS One (2015) 0.75
Association of Sicca Syndrome with Proviral Load and Proinflammatory Cytokines in HTLV-1 Infection. J Immunol Res (2016) 0.75
Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A (1980) 30.08
Global epidemiology of HTLV-I infection and associated diseases. Oncogene (2005) 4.77
Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis (2007) 3.80
The risk of development of HTLV-I-associated myelopathy/tropical spastic paraparesis among persons infected with HTLV-I. J Acquir Immune Defic Syndr (1990) 2.65
Chronic inflammatory arthropathy associated with HTLV-I. Lancet (1989) 2.28
HTLV-I in the general population of Salvador, Brazil: a city with African ethnic and sociodemographic characteristics. J Acquir Immune Defic Syndr (2003) 1.70
HTLV-1 and polymyositis in Jamaica. Lancet (1989) 1.51
Prevalence and clinical features of HTLV neurologic disease in the HTLV Outcomes Study. Neurology (2003) 1.51
Respiratory and urinary tract infections, arthritis, and asthma associated with HTLV-I and HTLV-II infection. Emerg Infect Dis (2004) 1.44
Immunopathogenesis of human T cell lymphotropic virus type I-associated neurologic disease. J Infect Dis (2002) 1.39
Exacerbated inflammatory cellular immune response characteristics of HAM/TSP is observed in a large proportion of HTLV-I asymptomatic carriers. BMC Infect Dis (2004) 1.39
Distribution of human T-lymphotropic virus type I among blood donors: a nationwide Brazilian study. Transfusion (1997) 1.32
Uveitis associated with human T lymphotropic virus type I: seroepidemiologic, clinical, and virologic studies. J Infect Dis (1992) 1.24
Clinical manifestations associated with HTLV type I infection: a cross-sectional study. AIDS Res Hum Retroviruses (2007) 1.20
Effect of human T-lymphotropic virus type I infection on non-Hodgkin's lymphoma incidence. J Natl Cancer Inst (1995) 1.19
HTLV-1 and associated adult T-cell leukemia/lymphoma. Rev Clin Exp Hematol (2003) 1.18
Cytokine profile and immunomodulation in asymptomatic human T-lymphotropic virus type 1-infected blood donors. J Acquir Immune Defic Syndr (2001) 1.15
HTLV-I/II prevalence in different geographic locations. Transfus Med Rev (2004) 1.14
Urodynamic features of the voiding dysfunction in HTLV-1 infected individuals. Int Braz J Urol (2007) 1.12
The neurology of HTLV-1 infection. Pract Neurol (2009) 1.07
Urinary and sexual manifestations of patients infected by HTLV-I. Clinics (Sao Paulo) (2007) 1.05
Dermatologic lesions in asymptomatic blood donors seropositive for human T cell lymphotropic virus type-1. Am J Trop Med Hyg (2003) 1.05
Conventional magnetic resonance imaging features in patients with tropical spastic paraparesis. J Neurovirol (2005) 1.03
Ocular manifestations of human T-cell lymphotropic virus type 1 infection. Curr Opin Ophthalmol (2003) 1.02
Human T lymphotropic virus type 1 (HTLV-1) proviral load in asymptomatic carriers, HTLV-1-associated myelopathy/tropical spastic paraparesis, and other neurological abnormalities associated with HTLV-1 infection. Clin Infect Dis (2007) 1.01
Brain magnetic resonance imaging white matter lesions are frequent in HTLV-I carriers and do not discriminate from HAM/TSP. AIDS Res Hum Retroviruses (2007) 0.99
Increased proviral load in HTLV-1-infected patients with rheumatoid arthritis or connective tissue disease. Retrovirology (2005) 0.98
Neurologic abnormalities in HTLV-I- and HTLV-II-infected individuals without overt myelopathy. Neurology (2009) 0.95
Prevalence of erectile dysfunction in HTLV-1-infected patients and its association with overactive bladder. Urology (2010) 0.95
Urinary symptoms associated with human T-cell lymphotropic virus type I infection: evidence of urinary manifestations in large group of HTLV-I carriers. Urology (2007) 0.95
Association of human T lymphotropic virus 1 amplification of periodontitis severity with altered cytokine expression in response to a standard periodontopathogen infection. Clin Infect Dis (2010) 0.92
Peripheral neuropathy in HTLV-I infected individuals without tropical spastic paraparesis/HTLV-I-associated myelopathy. J Neurol (2004) 0.92
Erectile dysfunction and HTLV-I infection: a silent problem. Int J Impot Res (2005) 0.90
Recent studies on the epidemiology, clinical features and pathogenic mechanisms of HTLV-I associated myelopathy (HAM/TSP) and other diseases associated to HTLV. J Neurovirol (1997) 0.88
Spontaneous neutrophil activation in HTLV-1 infected patients. Braz J Infect Dis (2006) 0.86
Infective dermatitis has similar immunological features to human T lymphotropic virus-type 1-associated myelopathy/tropical spastic paraparesis. Clin Exp Immunol (2009) 0.86
Clinical features of human T-lymphotropic virus type 1 uveitis: a long-term follow-up. Ocul Immunol Inflamm (2000) 0.86
The peripheral nervous system complications of HTLV-1 myelopathy (HAM/TSP) syndromes. Semin Neurol (2005) 0.85
Study of autoantibodies in patients with keratoconjunctivitis sicca infected by the human T cell lymphotropic virus type 1. Rheumatol Int (2009) 0.81
Neurological manifestations in HTLV-I-infected blood donors. J Neurol Sci (2003) 0.79
Up-regulation of Th1-type responses in mucosal leishmaniasis patients. Infect Immun (2002) 2.90
Vitamin D deficiency in HIV-infected and HIV-uninfected women in the United States. J Acquir Immune Defic Syndr (2011) 2.65
Decreased in situ expression of interleukin-10 receptor is correlated with the exacerbated inflammatory and cytotoxic responses observed in mucosal leishmaniasis. Infect Immun (2005) 2.29
Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr (2004) 2.21
Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis. Clin Infect Dis (2007) 2.08
Disseminated leishmaniasis: a new and emerging form of leishmaniasis observed in northeastern Brazil. J Infect Dis (2002) 2.06
Prevalence of clinical symptoms associated with highly active antiretroviral therapy in the Women's Interagency HIV Study. Clin Infect Dis (2004) 1.94
Activated inflammatory T cells correlate with lesion size in human cutaneous leishmaniasis. Immunol Lett (2005) 1.94
Enhanced Leishmania braziliensis infection following pre-exposure to sandfly saliva. PLoS Negl Trop Dis (2007) 1.63
Failure of early treatment of cutaneous leishmaniasis in preventing the development of an ulcer. Clin Infect Dis (2002) 1.60
Epidemiologic and immunologic findings for the subclinical form of Leishmania braziliensis infection. Clin Infect Dis (2002) 1.51
Mucosal leishmaniasis: epidemiological and clinical aspects. Braz J Otorhinolaryngol (2008) 1.49
Serial quantitative PCR assay for detection, species discrimination, and quantification of Leishmania spp. in human samples. J Clin Microbiol (2011) 1.48
Clinical and immunologic evaluation of 31 patients with acute schistosomiasis mansoni. J Infect Dis (2001) 1.44
Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial. PLoS Negl Trop Dis (2010) 1.40
Exacerbated inflammatory cellular immune response characteristics of HAM/TSP is observed in a large proportion of HTLV-I asymptomatic carriers. BMC Infect Dis (2004) 1.39
IL6 -174 G/C promoter polymorphism influences susceptibility to mucosal but not localized cutaneous leishmaniasis in Brazil. J Infect Dis (2006) 1.38
A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. AIDS Res Hum Retroviruses (2005) 1.37
Osteonecrosis in HIV disease: epidemiology, etiologies, and clinical management. AIDS (2003) 1.28
Reappraisal of the immunopathogenesis of disseminated leishmaniasis: in situ and systemic immune response. Trans R Soc Trop Med Hyg (2011) 1.27
Schistosoma mansoni infection is associated with a reduced course of asthma. J Allergy Clin Immunol (2003) 1.24
Fractures after antiretroviral initiation. AIDS (2012) 1.21
Assessing mortality in women with hepatitis C virus and HIV using indirect markers of fibrosis. AIDS (2012) 1.21
Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095). J Acquir Immune Defic Syndr (2007) 1.20
Clinical manifestations associated with HTLV type I infection: a cross-sectional study. AIDS Res Hum Retroviruses (2007) 1.20
Impaired T helper 2 response to aeroallergen in helminth-infected patients with asthma. J Infect Dis (2004) 1.17
Schistosoma mansoni antigens modulate experimental allergic asthma in a murine model: a major role for CD4+ CD25+ Foxp3+ T cells independent of interleukin-10. Infect Immun (2008) 1.16
Association of type 2 cytokines with hepatic fibrosis in human Schistosoma mansoni infection. Infect Immun (2004) 1.15
IL-17 mediates immunopathology in the absence of IL-10 following Leishmania major infection. PLoS Pathog (2013) 1.15
Association of treatment of American cutaneous leishmaniasis prior to ulcer development with high rate of failure in northeastern Brazil. Am J Trop Med Hyg (2009) 1.14
Protective and pathologic immune responses in human tegumentary leishmaniasis. Front Immunol (2012) 1.13
Urodynamic features of the voiding dysfunction in HTLV-1 infected individuals. Int Braz J Urol (2007) 1.12
Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus. J Infect Dis (2005) 1.12
Interleukin 17 production among patients with American cutaneous leishmaniasis. J Infect Dis (2009) 1.12
Resistance of Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis to nitric oxide correlates with disease severity in Tegumentary Leishmaniasis. BMC Infect Dis (2007) 1.11
Epidemiological and clinical changes in American tegumentary leishmaniasis in an area of Leishmania (Viannia) braziliensis transmission over a 20-year period. Am J Trop Med Hyg (2012) 1.11
Influence of helminth infections on the clinical course of and immune response to Leishmania braziliensis cutaneous leishmaniasis. J Infect Dis (2006) 1.11
Human classical monocytes control the intracellular stage of Leishmania braziliensis by reactive oxygen species. J Infect Dis (2014) 1.09
Evidence of in situ cytotoxicity in American cutaneous leishmaniasis. Eur J Dermatol (2002) 1.09
Association of HIV infection with incident diabetes mellitus: impact of using hemoglobin A1C as a criterion for diabetes. J Acquir Immune Defic Syndr (2012) 1.08
Low bone mineral density, HIV infection, and women: fracture or fiction? Clin Infect Dis (2006) 1.07
Risk factors for thrombocytopenia in HIV-infected persons in the era of potent antiretroviral therapy. J Acquir Immune Defic Syndr (2009) 1.07
Urinary and sexual manifestations of patients infected by HTLV-I. Clinics (Sao Paulo) (2007) 1.05
A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS (2010) 1.05
Recent developments leading toward a paradigm switch in the diagnostic and therapeutic approach to human leishmaniasis. Curr Opin Infect Dis (2008) 1.05
Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals. AIDS Res Hum Retroviruses (2010) 1.04
Macrophages participate in host protection and the disease pathology associated with Leishmania braziliensis infection. BMC Infect Dis (2012) 1.04
Metabolic syndrome before and after initiation of antiretroviral therapy in treatment-naive HIV-infected individuals. J Acquir Immune Defic Syndr (2012) 1.03
Geographic clustering of leishmaniasis in northeastern Brazil. Emerg Infect Dis (2009) 1.02
Effects of smoking on non-AIDS-related morbidity in HIV-infected patients. Clin Infect Dis (2013) 1.01
Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection. J Acquir Immune Defic Syndr (2002) 1.01
Total hip arthroplasty in patients with human immunodeficiency virus infection: pathologic findings and surgical outcomes. Acta Orthop (2005) 1.00
Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study. J Infect Dis (2013) 0.99
Association of hepatitis C virus and HIV infection with subclinical atherosclerosis in the women's interagency HIV study. AIDS (2009) 0.99
Brain magnetic resonance imaging white matter lesions are frequent in HTLV-I carriers and do not discriminate from HAM/TSP. AIDS Res Hum Retroviruses (2007) 0.99
CXCR1 and SLC11A1 polymorphisms affect susceptibility to cutaneous leishmaniasis in Brazil: a case-control and family-based study. BMC Med Genet (2010) 0.99
Resistance of Leishmania (Viannia) braziliensis to nitric oxide: correlation with antimony therapy and TNF-alpha production. BMC Infect Dis (2010) 0.97
Management of the metabolic effects of HIV and HIV drugs. Nat Rev Endocrinol (2011) 0.97
IFN-γ production to leishmania antigen supplements the leishmania skin test in identifying exposure to L. braziliensis infection. PLoS Negl Trop Dis (2012) 0.97
Characterization of the immune response to Leishmania infantum recombinant antigens. Microbes Infect (2003) 0.97
Cost-effectiveness of diagnostic for malaria in Extra-Amazon Region, Brazil. Malar J (2012) 0.96
The cause of urinary symptoms among Human T Lymphotropic Virus Type I (HLTV-I) infected patients: a cross sectional study. BMC Infect Dis (2007) 0.96
Urinary symptoms associated with human T-cell lymphotropic virus type I infection: evidence of urinary manifestations in large group of HTLV-I carriers. Urology (2007) 0.95
Prevalence of erectile dysfunction in HTLV-1-infected patients and its association with overactive bladder. Urology (2010) 0.95
The -2518bp promoter polymorphism at CCL2/MCP1 influences susceptibility to mucosal but not localized cutaneous leishmaniasis in Brazil. Infect Genet Evol (2010) 0.95
Glycemic control in HIV-infected patients with diabetes mellitus and rates of meeting American Diabetes Association management guidelines. AIDS Patient Care STDS (2011) 0.95
Immune responses to an inactive vaccine against American cutaneous leishmaniasis together with granulocyte-macrophage colony-stimulating factor. Vaccine (2002) 0.94
Schistosoma mansoni infection modulates the immune response against allergic and auto-immune diseases. Mem Inst Oswaldo Cruz (2004) 0.94
Wound healing genes and susceptibility to cutaneous leishmaniasis in Brazil. Infect Genet Evol (2012) 0.94
Association between obesity measured by different parameters and severity of psoriasis. Int J Dermatol (2012) 0.94
Differential effects of antigens from L. braziliensis isolates from disseminated and cutaneous leishmaniasis on in vitro cytokine production. BMC Infect Dis (2006) 0.94
Isolated hepatitis B core antibody is associated with HIV and ongoing but not resolved hepatitis C virus infection in a cohort of US women. J Infect Dis (2007) 0.93
Cutaneous leishmaniasis during pregnancy: exuberant lesions and potential fetal complications. Clin Infect Dis (2007) 0.93
Vitamin D insufficiency may impair CD4 recovery among Women's Interagency HIV Study participants with advanced disease on HAART. AIDS (2013) 0.92
Association between an emerging disseminated form of leishmaniasis and Leishmania (Viannia) braziliensis strain polymorphisms. J Clin Microbiol (2012) 0.92
Spatial analysis and risk mapping of soil-transmitted helminth infections in Brazil, using Bayesian geostatistical models. Geospat Health (2013) 0.91
Prevention strategies for cardiovascular disease in HIV-infected patients. Circulation (2008) 0.91
Case-control study of diabetes mellitus in HIV-infected patients. J Acquir Immune Defic Syndr (2004) 0.91
Successful treatment of refractory cutaneous leishmaniasis with GM-CSF and antimonials. Am J Trop Med Hyg (2005) 0.91
Flower cells in patients with infective dermatitis associated with HTLV-1. J Clin Virol (2010) 0.91
Zinc/copper imbalance reflects immune dysfunction in human leishmaniasis: an ex vivo and in vitro study. BMC Infect Dis (2004) 0.91
Lower liver-related death in African-American women with human immunodeficiency virus/hepatitis C virus coinfection, compared to Caucasian and Hispanic women. Hepatology (2012) 0.91
Evaluation of IFN-gamma and TNF-alpha as immunological markers of clinical outcome in cutaneous leishmaniasis. Rev Soc Bras Med Trop (2002) 0.91
Clinical and immunological outcome in cutaneous leishmaniasis patients treated with pentoxifylline. Am J Trop Med Hyg (2014) 0.90
The relationship between race and HIV-distal sensory polyneuropathy in a large cohort of US women. J Neurol Sci (2011) 0.90
Factors associated with smoking in HIV-infected patients and potential barriers to cessation. AIDS Patient Care STDS (2013) 0.90